Table 1 Socio-demographic and clinical data of LGV cases starting from 2011 until end of June 2017
2011 n(%) | 2012 n(%) | 2013 n(%) | 2014 n(%) | 2015 n(%) | 2016 n(%) | S1 2017 n(%) | TOTAL | |
|---|---|---|---|---|---|---|---|---|
Number of LGV cases | 21 | 23 | 45 | 58 | 62 | 88 | 46 | 343 |
Gender | 343/343 known | |||||||
Male or Trans female | 21 (100%) | 23 (100%) | 45 (100%) | 58 (100%) | 61 (98%) | 88 (100%) | 46 (100%) | 342 (99,7%) |
Female | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (0,3%) |
Transmission of all men | 241/343 known | |||||||
MSM | 13 (100%) | 13 (100%) | 26 (100%) | 42 (100%) | 52 (98%) | 55 (98%) | 37 (97%) | 238 (99%) |
HETERO | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 1 (2%) | 1 (3%) | 3 (1%) |
Age scale | 343/343 known | |||||||
20–30 | 3 (14%) | 5(22%) | 2 (4%) | 10 (17%) | 17 (27%) | 14 (16%) | 6 (13%) | 57 (17%) |
31–40 | 7 (33%) | 7 (30%) | 17 (38%) | 28 (48%) | 14 (23%) | 27 (31%) | 17 (37%) | 117 (34%) |
41–50 | 8 (38%) | 8 (35%) | 21 (47%) | 15 (26%) | 17 (27%) | 27 (31%) | 14 (30%) | 110 (32%) |
51–60 | 2 (10%) | 3 (13%) | 5 (11%) | 4 (7%) | 14 (23%) | 18 (20%) | 8 (17%) | 54 (16%) |
> 61 | 1 (5%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 2 (2%) | 1 (2%) | 5 (1%) |
Geographical location in Belgium | 338/343 known | |||||||
Living in Flemish region | 17 (81%) | 20 (91%) | 37 (84%) | 36 (63%) | 47 (76%) | 61 (69%) | 36 (81%) | 254 (75%) |
Living in French region | 2 (10%) | 1 (5%) | 2 (5%) | 3 (5%) | 7 (11%) | 11 (12%) | 3 (7%) | 29 (9%) |
Living in the capital region | 2 (10%) | 1 (5%) | 5 (11%) | 18 (32%) | 8 (13%) | 16 (18%) | 5 (11%) | 55 (16%) |
Kind of Sample | 337/343 known | |||||||
Anorectal | 17 (85%) | 22 (96%) | 37 (86%) | 51 (89%) | 56 (92%) | 84 (95%) | 40 (89%) | 307 (91%) |
Genital | 3 (15%) | 1 (4%) | 3 (7%) | 6 (11%) | 2 (3%) | 3 (3%) | 2 (4%) | 20 (6%) |
Urine | 0 (0%) | 0 (0%) | 2 (5%) | 0 (0%) | 3 (5%) | 1 (1%) | 1 (2%) | 7 (2%) |
Inguinal | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 2 (1%) |
Eye fluid | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 1 (0,3%) |
HIV Status | 308/343 known | |||||||
Positive | 18 (100%) | 20 (100%) | 40 (95%) | 45 (88%) | 45 (75%) | 63 (84%) | 30 (71%) | 261 (85%) |
Negative | 0 (0%) | 0 (0%) | 2 (5%) | 6 (12%) | 15 (25%) | 12 (16%) | 12 (29%) | 47 (15%) |
Symptoms | 232/343 known | |||||||
Proctitis | 6 (75%) | 2 (50%) | 19 (63%) | 40 (89%) | 43 (81%) | 41 (76%) | 25 (66%) | 176 (76%) |
Inguinal lymphadenopathy or ulcer | 0 (0%) | 1 (25%) | 3 (10%) | 0 (0%) | 3 (6%) | 2 (4%) | 3 (8%) | 12 (5%) |
Other abdominal symptomsa | 0 (0%) | 0 (0%) | 3 (10%) | 3 (7%) | 3 (6%) | 0 (0%) | 1 (3%) | 10 (4%) |
Genital Ulcer | 2 (25%) | 0 (0%) | 1 (3%) | 1 (2%) | 0 (0%) | 1 (2%) | 1 (3%) | 6 (3%) |
Urethritis | 0 (0%) | 0 (0%) | 1 (3%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (1%) |
Other symptomsb | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 2 (5%) | 3 (1%) |
Asymptomatic | 0 (0%) | 1 (25%) | 3 (10%) | 0 (0%) | 4 (8%) | 9 (17%) | 6 (16%) | 23 (10%) |
Co-infections other than HIV | 197/343 known | |||||||
None | 6 (40%) | 0 (0%) | 2 (9%) | 7 (25%) | 17 (40%) | 20 (37%) | 10 (33%) | 62 (31%) |
Only one | 6 (40%) | 5 (83%) | 20 (91%) | 21 (75%) | 24 (57%) | 34 (63%) | 15 (50%) | 125 (63%) |
Two or more | 3 (20%) | 1 (17%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 5 (17%) | 10 (5%) |
Gonorrhea | 4 (24%) | 5 (71%) | 11 (41%) | 13 (41%) | 9 (19%) | 17 (28%) | 10 (28%) | 69 (35%) |
Syphilis | 2 (12%) | 2 (29%) | 9 (33%) | 4 (13%) | 8 (17%) | 9 (15%) | 6 (17%) | 40 (20%) |
Hepatitis C | 2 (12%) | 0 (0%) | 4 (15%) | 6 (19%) | 7 (15%) | 10 (17%) | 0 (0%) | 29 (15%) |
Chlamydia A-K | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3%) | 4 (9%) | 0 (0%) | 4 (11%) | 9 (5%) |
Hepatitis B | 2 (12%) | 0 (0%) | 1 (4%) | 1 (3%) | 0 (0%) | 1 (2%) | 2 (6%) | 7 (4%) |
Genital herpes | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (4%) | 0 (0%) | 1 (3%) | 3 (2%) |
Otherc | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (5%) | 3 (8%) | 7 (4%) |